EPH151 Prevalence of Risk Factors for Serious Adverse Events Among Rheumatoid Arthritis Patients Prescribed Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors: A Merative Marketscan Cross-Sectional Study
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1193
https://www.valueinhealthjournal.com/article/S1098-3015(23)04323-1/fulltext
Title :
EPH151 Prevalence of Risk Factors for Serious Adverse Events Among Rheumatoid Arthritis Patients Prescribed Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors: A Merative Marketscan Cross-Sectional Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04323-1&doi=10.1016/j.jval.2023.09.1193
First page :
Section Title :
Open access? :
No
Section Order :
10677